Gene Synthesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, By Method (Solid-phase Synthesis, Chip-based Synthesis, PCR-based Enzyme Synthesis), By Service (Antibody DNA Synthesis, Viral DNA Synthesis, Others), By Application (Gene & Cell Therapy Development, Vaccine Development, Disease Diagnosis, Others), By End Use (Biotechnology and Pharmaceutical Companies, Academic and Government Research Institutes, Contract Research Organizations), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.11 Billion
CAGR (2026-2031)	9.96%
Fastest Growing Segment	Solid-phase Synthesis
Largest Market	North America
Market Size (2031)	USD 3.73 Billion

Market Overview

The Global Gene Synthesis Market will grow from USD 2.11 Billion in 2025 to USD 3.73 Billion by 2031 at a 9.96% CAGR. Gene synthesis is defined as the de novo chemical engineering of double-stranded DNA sequences without reliance on a natural template, enabling the precise construction of complex genes and genomes for biological research. The market is primarily supported by the escalating demand for personalized therapeutic regimens, the critical need for rapid vaccine development, and robust financial inflows into the life sciences sector which fuel research and development. According to SynBioBeta, in 2024, venture investment in the synthetic biology sector reached $12.2 billion, reflecting a strong resurgence in the capital funding necessary to sustain industrial growth and technological innovation.

Despite this positive trajectory, the market faces a significant challenge regarding biosecurity risks associated with the potential misuse of synthetic DNA. Concerns over the accidental or intentional creation of harmful pathogens have led governments and international bodies to implement rigorous regulatory frameworks and screening protocols. These compliance requirements increase operational costs and create administrative burdens for manufacturers, which can delay production timelines and potentially impede the broader expansion of the global gene synthesis market.

Key Market Drivers

Technological advancements in high-throughput DNA synthesis platforms are significantly accelerating the adoption of synthetic biology across industrial and research settings. Innovations in silicon-based and enzymatic synthesis allow for the mass production of complex, high-fidelity gene sequences with reduced turnaround times, effectively removing historical bottlenecks in the design-build-test-learn cycle. This operational scalability allows commercial providers to meet the intensifying volume requirements of researchers who increasingly outsource the construction of variant libraries and metabolic pathways. According to Twist Bioscience, November 2024, in the 'Twist Bioscience Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results', the company shipped approximately 772,000 genes during the fiscal year, demonstrating a marked increase in the utilization of scalable synthesis technologies compared to the prior reporting period.

The expansion of gene and cell therapy clinical development pipelines further anchors the market, creating a sustained requirement for GMP-grade synthetic DNA used in viral vector production and mRNA therapeutic templates. As pharmaceutical companies advance candidates from discovery phases into regulated clinical trials, the demand for precise genetic material to ensure therapeutic safety and efficacy rises proportionally. According to the American Society of Gene + Cell Therapy, April 2024, in the 'Gene, Cell, & RNA Therapy Landscape: Q1 2024 Quarterly Report', the global development pipeline expanded to include 4,016 gene, cell, and RNA therapies, underscoring the massive scale of raw material needs. To support this therapeutic trajectory, newer market entrants are capitalizing on investor interest to enhance manufacturing capacities. According to Elegen, in 2024, the company secured $35 million in Series B financing to commercialize its proprietary cell-free DNA manufacturing infrastructure.

Download Free Sample Report

Key Market Challenges

The global gene synthesis market encounters significant impediments due to biosecurity risks associated with the potential misuse of synthetic DNA. Concerns regarding the engineering of harmful pathogens have necessitated the enforcement of strict regulatory frameworks and screening protocols. These compliance mandates force manufacturers to integrate costly and time-consuming verification systems into their workflows, which directly increases operational overhead and extends product turnaround times.

The burden of these security measures disproportionately affects market agility and scalability. Companies must allocate substantial resources to administrative vetting processes and "Know Your Customer" checks rather than focusing entirely on production speed or technological advancement. According to the International Gene Synthesis Consortium, in 2024, more than 40 major gene synthesis providers have committed to the Harmonized Screening Protocol to align with these rigorous biosecurity standards. While this widespread compliance is critical for maintaining public safety, the resulting increase in procedural complexity acts as a functional drag on manufacturing efficiency, thereby restraining the overall growth potential of the gene synthesis industry.

Key Market Trends

The emergence of DNA data storage as a novel application vertical is reshaping the market by addressing the critical limitations of traditional digital archiving. As global data generation outpaces the capacity of magnetic and silicon-based media, synthetic DNA offers an alternative with exceptional volumetric density and durability suitable for preserving information for millennia. This application demands the synthesis of vast quantities of coding oligonucleotides, creating a new high-volume revenue stream for gene synthesis providers distinct from biological research needs. According to Twist Bioscience, May 2025, in the 'Twist Bioscience Spins Out DNA Data Storage as Independent Company' press release, the organization secured $155 million in seed financing for its new subsidiary, Atlas Data Storage, to commercialize this archival technology and meet the growing demand for long-term data preservation.

The adoption of decentralized benchtop DNA printing platforms represents a fundamental shift from the centralized service model to on-site manufacturing. Laboratories are increasingly integrating automated synthesizers to produce genetic material within their own facilities, thereby eliminating shipping delays and mitigating intellectual property risks associated with outsourcing. This transition allows researchers to iterate designs rapidly, compressing development timelines for vaccines and metabolic engineering projects without relying on external vendors. According to Telesis Bio, March 2025, in the 'Telesis Bio Raises $21 Million from Novalis LifeSciences and Northpond Ventures' announcement, the company secured this capital specifically to accelerate the commercial adoption of its automated benchtop synthesis systems, highlighting the industry's strategic pivot toward distributed manufacturing capabilities.

Segmental Insights

Based on recent industry analysis, the Solid-phase Synthesis segment is identified as the fastest-growing category within the Global Gene Synthesis Market. This accelerated expansion is primarily driven by the method's proven reliability and high fidelity, which are critical for clinical-grade applications such as gene therapy and vaccine development. Unlike emerging techniques, solid-phase chemistry ensures the precise sequence verification required by regulatory frameworks for biopharmaceutical production. Furthermore, the integration of automation has significantly enhanced scalability and cost-efficiency, fueling the segment's rapid adoption among major pharmaceutical entities and research institutions globally.

Regional Insights

North America maintains a leading position in the global gene synthesis market due to established infrastructure and extensive research activities. This dominance is supported by significant government funding for synthetic biology from organizations such as the National Institutes of Health. Additionally, the region experiences high demand for genomic applications in drug discovery and personalized medicine. The presence of major biotechnology firms and a structured regulatory environment under the US Food and Drug Administration further accelerates market development. These factors collectively foster a favorable climate for innovation and commercial growth in the gene synthesis sector.

Recent Developments

• In October 2024, Twist Bioscience Corporation formed a collaborative partnership with Absci Corporation to co-design a novel therapeutic antibody using advanced technologies from both companies. The project combines Absci's generative AI drug creation platform with Twist's silicon-based DNA synthesis capabilities to create and validate new antibody candidates against a specific target. Twist Bioscience will contribute its synthesis tools, including Multiplexed Gene Fragments, to facilitate the rapid testing and verification of the AI-designed sequences. This collaboration highlights the increasing integration of artificial intelligence and high-throughput gene synthesis in the discovery of biologic drugs, aiming to streamline the development of effective new therapies.
• In July 2024, Ansa Biotechnologies announced the commercial availability of its proprietary enzymatic synthesis products, specifically the Ansa Clonal DNA and Ansa DNA Fragments. These offerings utilize a unique, enzyme-based approach that enables the production of complex DNA sequences without the limitations often associated with traditional chemical synthesis methods. The launch followed a successful early access program and allows researchers to obtain sequence-perfect clonal DNA and verified linear double-stranded DNA fragments. This development is significant for the gene synthesis market as it provides a solution for synthesizing difficult sequences, such as those with high complexity or repetition, which are essential for advancing applications in synthetic biology and genomic research.
• In June 2024, GenScript Biotech Corporation announced the launch of its FLASH Gene service, a new offering designed to accelerate gene synthesis workflows for researchers. This service provides an expedited turnaround time, delivering plasmid constructs from sequence to final product in as few as four business days. By utilizing advanced automation and optimized processes, the company aims to support rapid research and discovery in fields such as antibody drug development, vaccine creation, and cell therapy. The FLASH Gene service addresses the growing industry demand for speed and efficiency in obtaining high-quality gene constructs, ensuring that scientists can expedite their experimental timelines.
• In January 2024, Elegen entered into a strategic collaboration and licensing agreement with GSK to integrate its proprietary cell-free DNA manufacturing technology into the pharmaceutical company's development of vaccines and medicines. The partnership focuses on leveraging Elegen's specialized DNA production capabilities to accelerate the discovery and clinical advancement of genetic medicines, including RNA-based therapies. Under the terms of the agreement, Elegen is eligible to receive up to $35 million in near-term financial support, fees, and purchase commitments. This arrangement also includes potential milestone payments related to the development of new product features and the possibility of a future equity investment by GSK.

Key Market Players

• OriGene Technologies, Inc.
• Integrated DNA Technologies, Inc.
• ProMab Biotechnologies, Inc.
• Thermo Fisher Scientific, Inc.
• ProteoGenix, Inc.
• Biomatik USA LLC
• Twist Bioscience Corp.
• Boster Biological Technology Inc.
• Brooks Automation, Inc.
• Genscript Corporation

By Method	By Service	By Application	By End Use	By Region
Solid-phase Synthesis Chip-based Synthesis PCR-based Enzyme Synthesis	Antibody DNA Synthesis Viral DNA Synthesis Others	Gene & Cell Therapy Development Vaccine Development Disease Diagnosis Others	Biotechnology and Pharmaceutical Companies Academic and Government Research Institutes Contract Research Organizations	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Gene Synthesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Gene Synthesis Market, By Method:

• Solid-phase Synthesis
• Chip-based Synthesis
• PCR-based Enzyme Synthesis

• Gene Synthesis Market, By Service:

• Antibody DNA Synthesis
• Viral DNA Synthesis
• Others

• Gene Synthesis Market, By Application:

• Gene & Cell Therapy Development
• Vaccine Development
• Disease Diagnosis
• Others

• Gene Synthesis Market, By End Use:

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Contract Research Organizations

• Gene Synthesis Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE